NASDAQ:APLM Apollomics (APLM) Stock Forecast, Price & News $3.76 +0.16 (+4.44%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$3.48▼$3.9050-Day Range$3.60▼$5.8252-Week Range$3.48▼$49.00Volume27,208 shsAverage Volume7,516 shsMarket Capitalization$326.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Apollomics (NASDAQ:APLM) StockApollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.Read More APLM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLM Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comApollomics, Inc. (NASDAQ:APLM) Short Interest UpdateJuly 30, 2023 | finance.yahoo.comAPLM - Apollomics, Inc.September 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.July 20, 2023 | finance.yahoo.comRetail investors account for 44% of Apollomics, Inc.'s (NASDAQ:APLM) ownership, while private equity firms account for 21%July 8, 2023 | fool.comApollomics (NASDAQ: APLM)June 19, 2023 | finance.yahoo.comQiming Venture Partners Welcomes Apollomics' Successful IPO on NasdaqJune 19, 2023 | finance.yahoo.comApollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller SymposiumSee More Headlines Receive APLM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLM Company Calendar Today9/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLM CUSIPN/A CIK1944885 Webwww.apollomicsinc.com Phone886-2-7713-7952FaxN/AEmployees43Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.51 Sales & Book Value Annual Sales$1.45 million Price / Sales225.08 Cash FlowN/A Price / Cash FlowN/A Book Value($33.37) per share Price / Book-0.11Miscellaneous Outstanding Shares86,800,000Free FloatN/AMarket Cap$326.37 million OptionableNot Optionable Beta0.94 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Guo-Liang Yu Ph.D. (Age 60)Co-Founder, CEO & Exec. Chairman Dr. Sanjeev Redkar MBA (Age 54)Ph.D., Co-Founder, Pres, CFO & Exec. Director Dr. Lijuan Jane Wang Ph.D. (Age 59)Chief Scientific Officer & GM of China Ms. Brianna MacDonald J.D.Sr. VP & Gen. CounselDr. Kin-Hung Yu M.D. (Age 61)Chief Medical Officer Dr. Chinglin Lai Ph.D.Sr. VP of Biostatistics & Data ManagementMore ExecutivesKey CompetitorsArbutus BiopharmaNASDAQ:ABUSPrecigenNASDAQ:PGENSIGA TechnologiesNASDAQ:SIGAKalVista PharmaceuticalsNASDAQ:KALVTerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInstitutional OwnershipBlackRock Inc.Bought 6,562 shares on 8/11/2023Ownership: 0.008%Levin Capital Strategies L.P.Bought 11,000 shares on 7/31/2023Ownership: 0.013%Exchange Traded Concepts LLCBought 29,552 shares on 7/20/2023Ownership: 0.034%View All Institutional Transactions APLM Stock - Frequently Asked Questions Should I buy or sell Apollomics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollomics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLM shares. View APLM analyst ratings or view top-rated stocks. How have APLM shares performed in 2023? Apollomics' stock was trading at $24.20 on January 1st, 2023. Since then, APLM stock has decreased by 84.5% and is now trading at $3.76. View the best growth stocks for 2023 here. Are investors shorting Apollomics? Apollomics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 4,100 shares, an increase of 57.7% from the August 15th total of 2,600 shares. Based on an average daily volume of 21,300 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's stock are sold short. View Apollomics' Short Interest. What ETF holds Apollomics' stock ? Range Cancer Therapeutics ETF holds 26,270 shares of APLM stock, representing 1.45% of its portfolio. What is Apollomics' stock symbol? Apollomics trades on the NASDAQ under the ticker symbol "APLM." Who are Apollomics' major shareholders? Apollomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.03%), Levin Capital Strategies L.P. (0.01%) and BlackRock Inc. (0.01%). How do I buy shares of Apollomics? Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Apollomics' stock price today? One share of APLM stock can currently be purchased for approximately $3.76. How much money does Apollomics make? Apollomics (NASDAQ:APLM) has a market capitalization of $326.37 million and generates $1.45 million in revenue each year. How can I contact Apollomics? Apollomics' mailing address is 5/F-4 NO. 89 SONGREN ROAD XINYI DISTRICT, TAIPEI CITY F5, 11073. The official website for the company is www.apollomicsinc.com. The company can be reached via phone at 886-2-7713-7952. This page (NASDAQ:APLM) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.